Matthew Wieduwilt is an Oncology physician affiliated with Atrium Health Wake Forest Baptist. OpenAlex indexes 145 publications with 6,691 citations (h-index 33); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Medical Center Blvd
Winston Salem, NC 271575418
Telephone
336-713-5440Provider last certified this registry record 19 Oct 2022.
Clinical trials
- Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments
- PFIZER INC.Program year20245 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
32.8%Serotonin-3 Receptor Antagonist16.4%Ondansetron Hcl100%Part D<11 patientsPotassium supplement16.4%Potassium Chloride100%Part D<11 patientsDermatology
31.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor31.3%Acyclovir100%Part D<11 patientsCancer & immunology
19.4%Nucleoside Metabolic Inhibitor19.4%Onureg100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Herrington, MD
Atrium Health Wake Forest Baptist
Bruce Lessey, MD
Atrium Health Wake Forest Baptist
David Hurd, MD
Atrium Health Wake Forest Baptist
Kevin High, MD
Atrium Health Wake Forest Baptist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”